I couldn't be more proud of these 💪exceptional graduates from the NIH Heme Onc Program. @NCICCR_MOS 👉Look out cancer, you have a new wave of brilliant & talented doctors sworn to wipe you out! ASCO National Cancer Institute @NCIResearchCtr @nih_nhlbi AACR Society for Immunotherapy of Cancer Congratulations! 🎉🎇

Thank you Ravi A Madan M.D.! It wouldn’t have been possible without your mentorship and the mentorship of Fatima Karzai, M.D. . Excited to be part of PCF Science Prostate Cancer Foundation

#kantofflab reunion at #PCFRetreat22 Phil Kantoff Elliot Mohammad Atiq, M.D. and Konrad

Dr. Elias Chandran Elias Chandran, MBBS presents unique data re: #immune changes after #docteaxel in #mCSPC #ProstateCancer @asco #GU23 today! Poster #F8 This data may highlight a better path forward for #Immunotherapy in Prostate Cancer. #NKcells meetings.asco.org/abstracts-pres…

Evidence on the immunomodulatory effect of docetaxel Elias Chandran, MBBS Mohammad Atiq, M.D. Fatima Karzai, M.D. Marijo Bilusic, MD, PhD @gulleyj1 Ravi A Madan M.D. ascopubs.org/doi/abs/10.120…

(1/n) Our latest work in Eur Urol Focus bit.ly/3YxpWnL is a retrospective study from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center reporting outcomes with ICT by CN status in patients with sarcomatoid and/or rhabdoid dediff Pavlos Msaouel ari hakimi Ritesh Kotecha

Last yr we noted the presumptions & peril of overtreatment of PSMA+(#BCR)#ProstateCancer bit.ly/3YHw5Ok "What is missing in this equation is knowledge of the natural history of #PSMA #PET+disease" A study to investigate this is now open @thenci bit.ly/3yxRcYQ

“Subgroups of pts such as those w/ dMMR/MSI-H locally advanced [#ProstateCancer] who may not be considered candidates for local treatment…may experience greater benefit from immune checkpoint inhibition than that expected with ADT alone.” #LynchSyndrome frontiersin.org/articles/10.33…

Emerging treatment options for #ProstateCancer Mohammad Atiq, M.D. Elias Chandran, MBBS Fatima Karzai, M.D. and Dr. Jeanny Aragon-Ching Inova Schar Cancer Institute tandfonline.com/eprint/UFVN4IT…

Dr Mohammad Atiq Mohammad Atiq, M.D. NCI CCR GU Malignancies @thenci will present a Trials In Progress poster tomorrow at the #ASCO23 #ProstateCancer Poster session ASCO 8-11am CDT Here is a link with more info on the trial: clinicaltrials.gov/ct2/show/NCT05… #PSMA #PET #imaging

A study of prospective monitoring of patients with recurrent #ProstateCancer using serial 18F-DCFPyL PSMA imaging. Presentation by Mohammad Atiq, M.D. NIH. #ASCO23 written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/43Ek4MH ASCO

#kantofflab get together at #PCFRetreart23. it's always great to meet with amazing friends in person, Konrad and Mohammad Atiq, M.D. PCF Science Prostate Cancer Foundation Phil Kantoff

Discussion of a case of oligometastatic prostate cancer by PSMA PET with Ana Aparicio Alok Tewari Thomas Hope Neha Vapiwala and team PCF Science. Addressing clinical questions that arise with novel technologies

Happy #InternalMedicineDay from ACP President Omar T. Atiq, M.D., MACP! Explore our I.M. Physician Toolkit for resources to spread the word about #InternalMedicine and celebrate our profession and why you are #IMProud to be an #IMPhysician: ow.ly/z36i50Q1M9C

We have already enrolled 55 patients in 6 months on this study evaluating serial #PSMA #imaging in #BCR #ProstateCancer National Cancer Institute Appreciate the support of referring docs who have sent us patients already & patients who have reached out Lots to learn clinicaltrials.gov/study/NCT05588…

Come join the team! The #ShafiLab Center for Prostate Disease Research is hiring personnel at postdoc and technician levels looking into mechanisms of circadian dysfunction, transcription, and DNA repair in #prostatecancer. DM me if you’re interested!

Proud of you Saad Atiq!!

Great experience! Looking forward to the next one with Nabiel Mir MBBS Abhinav Sidana

#kantofflab at #PCFRetreat24 , yearly photo tradition Mohammad Atiq, M.D. #konrad Elliot Abramowitz Phil Kantoff PCF Science Prostate Cancer Foundation #retreat

Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. bit.ly/4hoXnCq